Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIIL: 99mTc-3PRGD2 SPECT/CT in Lung Cancer
NCT04233476Phase 3Completed
- Sponsor
- RDO Pharm
- Start
- Oct 2019
- Primary completion
- May 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of 99mTc-3PRGD2 in lung cancer, lymph node metastasis, sponsored by RDO Pharm. Started Oct 2019; status: completed.
02
Drugs
99mTc-3PRGD2
03
Conditions
lung cancerlymph node metastasis
Beyond the preview
Go deeper on NCT04233476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04233476.